离子型谷氨酸受体的变构调节：治疗中枢神经系统疾病新治疗方法的展望
Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders.
作者信息
Brogi Simone, Campiani Giuseppe, Brindisi Margherita, Butini Stefania
机构信息
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, DoE Department of Excellence 2018-2022, via Aldo Moro 2, I-53100 Siena, Italy.
Department of Pharmacy, University of Napoli Federico II, DoE Department of Excellence 2018-2022, Via D. Montesano 49, 80131 Napoli, Italy.
出版信息
ACS Med Chem Lett. 2019 Jan 23;10(3):228-236. doi: 10.1021/acsmedchemlett.8b00450. eCollection 2019 Mar 14.
Abstract
The allosteric targeting of ionotropic glutamate receptors (iGluRs) is a valuable approach for treating various central nervous system (CNS) disorders. In this frame, this Innovations provides a summary of the state-of-the art in the development of allosteric modulators for iGluRs and offers an outlook regarding innovative strategies for treating neurological diseases.
摘要
对离子型谷氨酸受体（iGluRs）进行变构靶向是治疗各种中枢神经系统（CNS）疾病的一种有价值的方法。在此背景下，本《创新》总结了iGluRs变构调节剂开发的最新进展，并对治疗神经疾病的创新策略进行了展望。
相似文献
1
Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders.
ACS Med Chem Lett. 2019 Jan 23;10(3):228-236. doi: 10.1021/acsmedchemlett.8b00450. eCollection 2019 Mar 14.
2
Deeper Insights into the Allosteric Modulation of Ionotropic Glutamate Receptors.
Neuron. 2016 Sep 21;91(6):1187-1189. doi: 10.1016/j.neuron.2016.09.013.
3
Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
Prog Mol Biol Transl Sci. 2013;115:61-121. doi: 10.1016/B978-0-12-394587-7.00002-6.
4
Supraspinal metabotropic glutamate receptors: a target for pain relief and beyond.
Eur J Neurosci. 2014 Feb;39(3):444-54. doi: 10.1111/ejn.12398.
5
Ionotropic and metabotropic glutamate receptor structure and pharmacology.
Psychopharmacology (Berl). 2005 Apr;179(1):4-29. doi: 10.1007/s00213-005-2200-z. Epub 2005 Feb 25.
6
Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential.
Pharmacol Ther. 2004 Dec;104(3):233-44. doi: 10.1016/j.pharmthera.2004.08.010.
7
Fragment-Based Approaches for Allosteric Metabotropic Glutamate Receptor (mGluR) Modulators.
Curr Top Med Chem. 2019;19(19):1768-1781. doi: 10.2174/1568026619666190808150039.
8
Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators.
Neuropharmacology. 2011 Jan;60(1):135-50. doi: 10.1016/j.neuropharm.2010.08.004. Epub 2010 Aug 14.
9
Identification of Potential Dual Negative Allosteric Modulators of Group I mGluR Family: A Shape Based Screening, ADME Prediction, Induced Fit Docking and Molecular Dynamics Approach Against Neurodegenerative Diseases.
Curr Top Med Chem. 2019;19(29):2687-2707. doi: 10.2174/1568026619666191105112800.
10
Methods for evaluation of positive allosteric modulators of glutamate AMPA receptors.
Methods Mol Biol. 2007;403:37-57. doi: 10.1007/978-1-59745-529-9_3.
引用本文的文献
1
Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today.
Pharmacol Biochem Behav. 2025 Mar;248:173967. doi: 10.1016/j.pbb.2025.173967. Epub 2025 Jan 31.
2
New Chemo-, Regio- and Stereoselective Reactions and Methods in Organic Synthesis.
Int J Mol Sci. 2024 Dec 14;25(24):13409. doi: 10.3390/ijms252413409.
3
Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Dec 20;135:111107. doi: 10.1016/j.pnpbp.2024.111107. Epub 2024 Aug 2.
4
Roles of AMPA receptors in social behaviors.
Front Synaptic Neurosci. 2024 Jul 11;16:1405510. doi: 10.3389/fnsyn.2024.1405510. eCollection 2024.
5
Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease.
Clin Transl Sci. 2024 Jul;17(7):e13852. doi: 10.1111/cts.13852.
6
5-Nitroisoxazoles in Reactions: A Novel Chemo- and Regioselective Approach to Isoxazole-Based Bivalent Ligands of AMPA Receptors.
Int J Mol Sci. 2023 Nov 9;24(22):16135. doi: 10.3390/ijms242216135.
7
New Allosteric Modulators of AMPA Receptors: Synthesis and Study of Their Functional Activity by Radioligand-Receptor Binding Analysis.
Int J Mol Sci. 2023 Jun 18;24(12):10293. doi: 10.3390/ijms241210293.
8
Modulatory mechanisms of TARP γ8-selective AMPA receptor therapeutics.
Nat Commun. 2023 Mar 25;14(1):1659. doi: 10.1038/s41467-023-37259-5.
9
Diversity of AMPA Receptor Ligands: Chemotypes, Binding Modes, Mechanisms of Action, and Therapeutic Effects.
Biomolecules. 2022 Dec 27;13(1):56. doi: 10.3390/biom13010056.
10
Novel Nanomolar Allosteric Modulators of AMPA Receptor of Bis(pyrimidine) Series: Synthesis, Biotesting and SAR Analysis.
Molecules. 2022 Nov 26;27(23):8252. doi: 10.3390/molecules27238252.
本文引用的文献
1
Structure, function, and allosteric modulation of NMDA receptors.
J Gen Physiol. 2018 Aug 6;150(8):1081-1105. doi: 10.1085/jgp.201812032. Epub 2018 Jul 23.
2
Where is crystallography going?
Acta Crystallogr D Struct Biol. 2018 Feb 1;74(Pt 2):152-166. doi: 10.1107/S2059798317016709.
3
( S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation.
J Med Chem. 2018 Mar 8;61(5):2124-2130. doi: 10.1021/acs.jmedchem.8b00099. Epub 2018 Feb 26.
4
7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency.
J Med Chem. 2018 Jan 11;61(1):251-264. doi: 10.1021/acs.jmedchem.7b01323. Epub 2017 Dec 19.
5
CP-101,606: An NR2B-Selective NMDA Receptor Antagonist.
CNS Drug Rev. 1998 Dec;4(4):307-322. doi: 10.1111/j.1527-3458.1998.tb00073.x.
6
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.
Neuropharmacology. 2018 Jan;128:351-365. doi: 10.1016/j.neuropharm.2017.10.032. Epub 2017 Oct 26.
7
Discovery of hidden allosteric sites as novel targets for allosteric drug design.
Drug Discov Today. 2018 Feb;23(2):359-365. doi: 10.1016/j.drudis.2017.10.001. Epub 2017 Oct 10.
8
Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481/CERC-611.
Biochem Pharmacol. 2018 Jan;147:191-200. doi: 10.1016/j.bcp.2017.09.015. Epub 2017 Oct 5.
9
Preclinical Characterization of ()-3-((3,4)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate -Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.
J Pharmacol Exp Ther. 2017 Dec;363(3):377-393. doi: 10.1124/jpet.117.242784. Epub 2017 Sep 27.
10
Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist.
ACS Chem Neurosci. 2017 Dec 20;8(12):2631-2647. doi: 10.1021/acschemneuro.7b00186. Epub 2017 Sep 5.
Zotero 插件